UBS analyst Colin Bristow downgrades Immunovant (NASDAQ:IMVT) from Buy to Neutral and lowers the price target from $7 to $5.
AstraZeneca Announced Tezspire Approved For Self-administration In The EU In A New Pre-filled Pen
AstraZeneca's Tezspire (tezepelumab) has received a positive opinion from the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma.
